Synchrony.

As opposed to most available data on recurrent oligomets, this retrospective look at outcomes following radiation to all sites of de novo oligometastatic prostate cancer in 43 men reports a promising rate of survival free from biochemical progression of 80% at a median follow-up of 4 years. | Huynh, JAMA Netw Open 2022